Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK6640 in Japanese patients with Alzheimer's disease
NCT03093519Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing KHK6640 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events up to 197 days. Started Mar 2017; status: completed.
02
Drugs
KHK6640
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03093519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093519.